ReviewNature reviews. Endocrinology2026
Kidney diseases and the thyroid: interactions and consequences.
Review in Nature reviews. Endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Proteomic organ-specific signatures, ageing traits, disease risks and genetic architecture in an East Asian population.EBioMedicine · 2026Article
- The long-overlooked effect of hypothyroidism on the global burden of non-communicable diseases.Nature reviews. Endocrinology · 2026Article
- Greater recognition required for thyroid disorders.Nature reviews. Endocrinology · 2026Article
- Unravelling Sarcopenia in Chronic Kidney Disease: From Pathogenesis to Diagnosis and Therapeutics.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Thyroid Hormone Indices and Histopathological Severity of Diabetic Nephropathy in Euthyroid Patients with Type 2 Diabetes: A Biopsy-Based Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep concern has been raised about the reduced survival rate in patients with renal impairment, and efforts to identify comorbidities that could delay its progression are of paramount importance. Among them, thyroid dysfunction has been postulated as one of the determinants of chronic kidney disease (CKD). It is worth noting that the relationship between the thyroid gland and the kidney is mutual. Although patients with CKD can exhibit changes in thyroid function tests that characterize non-thyroidal illness syndrome, thyroid hormones per se are critical regulators of kidney structure and function. A growing number of studies indicate that subclinical hypothyroidism is more common in people with CKD than in the general population and could be considered a risk factor for the development of CKD. However, it remains unclear whether hypothyroidism has a causal role in the development of CKD or whether levothyroxine treatment could minimize the progressive loss of kidney function in these patients. Overall, this narrative Review intends to explore the potential involvement of thyroid dysfunction, with a focus on hypothyroidism, as a reversible risk condition in the deterioration of renal function.
Indexed as
Identifiers
41249474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.